BTIG Maintains Buy on United Therapeutics, Raises Price Target to $768
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
BTIG analyst Julian Harrison maintains United Therapeutics (NASDAQ:UTHR) with a Buy and raises the price target from $728 to $768.
BTIG analyst Julian Harrison maintains United Therapeutics (NASDAQ:UTHR) with a Buy and raises the price target from $728 to $768.